Ziopharm Oncology to Present Update on Controlled IL-12 Brain Cancer Trial at Annual Meeting of the Society for Neuro-Oncology on Nov. 16
A poster entitled, “A Phase 1 study of Ad-RTS-hIL-12 + veledimex in adults with recurrent glioblastoma: Dose determination with updated overall survival,” will be presented
Ziopharm’s presentation at SNO 2018 will include updated survival data for a group of 15 patients who received Ad-RTS-hIL-12 during surgical resection and the 20mg dose of veledimex, as well as the group of patients who received stereotactic administration of Ad-RTS-hIL-12. Additionally, the Company will present further analysis of the effect of dexamethasone, as data suggests that lower versus higher dose of steroids improves overall survival.
Ziopharm’s Ad-RTS-hIL-12 plus veledimex construct is designed to express human interleukin 12 (hIL-12) under the control of an orally administered activator ligand, veledimex through a proprietary RheoSwitch Therapeutic System® (RTS®) gene switch. Data from this Phase 1 trial previously revealed a median overall survival (mOS) of 12.7 months for patients treated with Ad-RTS-hIL-12 plus 20mg of veledimex (n=15) at a mean follow-up time of 12.9 months as of May 4, 2018. The mOS of 12.7 months compares favorably to the 5 to 8 months survival established in historical controls for patients with rGBM. At SNO 2017, biopsy data from this study showed consistent, dose-dependent production of recombinant IL-12 leading to production of interferon gamma, an influx of CD3+ CD8+ cytotoxic T cells, and upregulation of PD-1 and PD-L1.
The evaluation of Ad-RTS-hIL-12 plus veledimex as a monotherapy to treat patients with rGBM continues as the Company is expanding the number of adult patients treated with 20mg of veledimex from 15 patients to up to 40, and a trial evaluating this treatment for pediatric patients with brain cancer is ongoing. Ziopharm also is conducting a Phase 1 trial to evaluate Ad-RTS-hIL-12 plus veledimex in combination with OPDIVO® (nivolumab), an immune checkpoint, or PD-1, inhibitor, in adult patients with rGBM.
Forward-Looking Statements Disclaimer
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." All such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied by, the forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s ability to advance certain activities; whether chimeric antigen receptor T cell (CAR-T) approaches, Ad-RTS-hIL-12, TCR and NK cell-based therapies, or any of other product candidates will advance further in the preclinical research or clinical trial process and whether and when, if at all, they will receive final approval from the
Vice President, Corporate Communications and Investor Relations
Vice President, Portfolio Strategy
Source: ZIOPHARM Oncology Inc